Market Overview

Oppenheimer Initiates Prothena With Outperform

Muddy Waters Shorts Prothena On Doubts Of Drug Candidate's Efficacy
Don't Let Offerings Blindside Your Thesis

Analysts at Oppenheimer initiated coverage on shares of Prothena (NASDAQ: PRTA) with a Outperform rating.

The target price for Prothena is set to $40.

Prothena shares have dropped 1.50% over the past 52 weeks, while the S&P 500 index has surged 16.93% in the same period.

Prothena's shares fell 0.71% to close at $20.94 yesterday.

Latest Ratings for PRTA

Aug 2017Evercore ISI GroupInitiates Coverage OnOutperform
Jul 2017JefferiesInitiates Coverage OnBuy
May 2017BTIG ResearchInitiates Coverage OnBuy

View More Analyst Ratings for PRTA
View the Latest Analyst Ratings

Posted-In: OppenheimerInitiation Analyst Ratings


Related Articles (PRTA)

View Comments and Join the Discussion!